Revumenib (SNDX-5613)

Catalog No.S8996 Batch:S899601

Print

Technical Data

Formula

C32H47FN6O4S
Molecular Weight 630.82 CAS No. 2169919-21-3
Solubility (25°C)* In vitro DMSO 25 mg/mL (39.63 mM)
Ethanol 25 mg/mL (39.63 mM)
Water Insoluble
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description Revumenib(SNDX-5613) is a potent and selective inhibitor of menin-MLL binding with a Ki of 0.15 nM. SNDX-5613 shows anti-proliferative activity against multiple cell lines harboring MLLr translocations (MV4;11, RS4;11, MOLM-13, KOPN-8) with IC50 values ranging from 10-20 nM.
Targets
menin-MLL binding [1]
0.15 nM(Ki)
In vitro

SNDX-5613  has anti-proliferative activity against multiple cell lines harboring MLLr translocations (MV4;11, RS4;11, MOLM-13, KOPN-8). SNDX-5613 doesn't inhibit growth of HL-60, a promyelocytic leukemia cell line lacking an MLL rearrangement , indicating selective activity towards leukemic cells lines that harbor MLL-rearranged (MLLr) fusion proteins.<sup><a class="sref" href="#s_ref">[1]</a></sup>
In vivo

SNDX-5613 treatment provides significant survival benefit and leukemic control in aggressive MOLM-13 xenografts nude rats.<sup><a class="sref" href="#s_ref">[1]</a></sup>

Protocol (from reference)

Cell Assay:

[1]
  • Cell lines

    MV4;11, RS4;11, MOLM-13, KOPN-8, HL-60

  • Concentrations

    1-100 nM

  • Incubation Time

    2 h

  • Method

    Multiple cell lines harboring MLLr translocations (MV4;11, RS4;11, MOLM-13, KOPN- 8) was used to assess the antiproliferative activity of SNDX-5613 against MLLr cell lines by standard cell proliferation assay.
Animal Study:

[1]
  • Animal Models

    MOLM-13 model rats

  • Dosages

    5, 15, 50 mg/kg

  • Administration

    Oral gavage

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.